Download PDF
Semin Thromb Hemost 2012; 38(02): 200-212
DOI: 10.1055/s-0032-1301417
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

High Platelet Reactivity and Antiplatelet Therapy Resistance

Matthew D. Linden
1   School of Medical Sciences and Health Innovations Research Institute, RMIT University, Melbourne, Australia
2   Department of Epidemiology and Preventative Medicine, Monash University, Melbourne, Australia
,
Huyen Tran
3   Australian Centre for Blood Diseases, Monash University, Melbourne, Australia
,
Robyn Woods
2   Department of Epidemiology and Preventative Medicine, Monash University, Melbourne, Australia
,
Andrew Tonkin
2   Department of Epidemiology and Preventative Medicine, Monash University, Melbourne, Australia
› Author Affiliations
Further Information

Publication History

Publication Date:
16 February 2012 (online)

    Permissions and Reprints

Abstract

The term resistance has been applied to interindividual variability in platelet reactivity during antiplatelet therapy or to thrombosis despite appropriate therapy. In particular “aspirin resistance” and “clopidogrel resistance” have been the subject of intense investigation for their association with poor cardiovascular outcomes. Several mechanisms have been investigated including resistance arising from poor bioavailability, especially in clopidogrel therapy as resulting from a loss of function variant in hepatic metabolism required for prodrug activation. A limitation of studies linking on-treatment reactivity and clinical outcome is that they have been performed in high-risk patients with recent atherothrombotic disease. On-treatment platelet reactivity correlates with acuity of recent atherothrombosis, and variability in pretreatment platelet function predicts on-treatment platelet function for both aspirin and clopidogrel. It is therefore likely that high on-treatment platelet function at the time of testing may often result from underlying platelet hyperreactivity related to acute atherothrombosis, rather than true pharmacological resistance. The association of high on-treatment platelet reactivity with poor clinical outcomes may therefore be attributed to variability in underlying burden of disease instead of, or in addition to, pharmacological resistance to antiplatelet therapy.

Keywords

aspirin resistance - clopidogrel resistance - platelet hyperreactivity - cardiovascular disease - antiplatelet therapy
 

  • References

  • 1 Lippi G, Franchini M, Targher G. Arterial thrombus formation in cardiovascular disease. Nat Rev Cardiol 2011; 8 (9) 502-512
    CrossrefPubMedGoogle Scholar
  • 2 Rosamond W, Flegal K, Friday G , et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115 (5) e69-e171
    CrossrefPubMedGoogle Scholar
  • 3 National Center for Health Statistics. Chartbook on Trends in the Health of Americans. Hyattsville, MD: : Library of Congress Catalog Number 76–641496;2007
    Google Scholar
  • 4 Goldschmidt PJ, Lopes N, Crawford LE, Becker RC. Atherothrombosis and coronary artery disease. In: Michelson AD, ed. Platelets. 2nd ed. San Diego: : Academic Press; ; 2007: 629-657
    CrossrefGoogle Scholar
  • 5 Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315 (16) 983-989
    CrossrefPubMedGoogle Scholar
  • 6 Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008; 359 (9) 938-949
    CrossrefPubMedGoogle Scholar
  • 7 Cattaneo M. ADP receptor agonists. In: Michelson AD, , ed. Platelets. 2nd ed. San Diego: : Elsevier/Academic Press; ; 2006: 1124-1144
    Google Scholar
  • 8 Lauri D, Cerletti C, de Gaetano G. Amplification of primary response of human platelets to platelet-activating factor: aspirin-sensitive and aspirin-insensitive pathways. J Lab Clin Med 1985; 105 (6) 653-658
    PubMedGoogle Scholar
  • 9 Hato T, Pampori N, Shattil SJ. Complementary roles for receptor clustering and conformational change in the adhesive and signaling functions of integrin alphaIIb beta3. J Cell Biol 1998; 141 (7) 1685-1695
    CrossrefPubMedGoogle Scholar
  • 10 Shattil SJ, Brass LF. Induction of the fibrinogen receptor on human platelets by intracellular mediators. J Biol Chem 1987; 262 (3) 992-1000
    PubMedGoogle Scholar
  • 11 Shattil SJ, Hoxie JA, Cunningham M, Brass LF. Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activation. J Biol Chem 1985; 260 (20) 11107-11114
    PubMedGoogle Scholar
  • 12 Linden MD, Jackson DE. Platelets: pleiotropic roles in atherogenesis and atherothrombosis. Int J Biochem Cell Biol 2010; 42 (11) 1762-1766
    CrossrefPubMedGoogle Scholar
  • 13 Huo Y, Schober A, Forlow SB , et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003; 9 (1) 61-67
    CrossrefPubMedGoogle Scholar
  • 14 Seizer P, Gawaz M, May AE. Platelet-monocyte interactions—a dangerous liaison linking thrombosis, inflammation and atherosclerosis. Curr Med Chem 2008; 15 (20) 1976-1980
    CrossrefPubMedGoogle Scholar
  • 15 Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol 2009; 54 (8) 669-677
    CrossrefPubMedGoogle Scholar
  • 16 Smith Jr SC, Feldman TE, Hirshfeld Jr JW , et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 113 (7) e166-e286
    CrossrefPubMedGoogle Scholar
  • 17 Patrono C, Baigent C, Hirsh J, Roth G ; American College of Chest Physicians. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6, Suppl) 199S-233S
    CrossrefPubMedGoogle Scholar
  • 18 Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A 1975; 72 (8) 3073-3076
    CrossrefPubMedGoogle Scholar
  • 19 Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975; 56 (3) 624-632
    CrossrefPubMedGoogle Scholar
  • 20 Baigent C, Blackwell L, Collins R , et al; Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373 (9678) 1849-1860
    CrossrefPubMedGoogle Scholar
  • 21 Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324 (7329) 71-86
    CrossrefPubMedGoogle Scholar
  • 22 Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov 2010; 9 (2) 154-169
    CrossrefPubMedGoogle Scholar
  • 23 Ajani UA, Ford ES, Greenland KJ, Giles WH, Mokdad AH. Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System. Am J Prev Med 2006; 30 (1) 74-77
    CrossrefPubMedGoogle Scholar
  • 24 U.S. Census of Population and Housing. 2010. Washington: : Government Printing Office; ; 2011
    Google Scholar
  • 25 Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK ; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345 (7) 494-502
    CrossrefPubMedGoogle Scholar
  • 26 Mehta SR, Yusuf S, Peters RJ , et al; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358 (9281) 527-533
    CrossrefPubMedGoogle Scholar
  • 27 Steinhubl SR, Berger PB, Mann III JT , et al; CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288 (19) 2411-2420
    CrossrefPubMedGoogle Scholar
  • 28 Chen ZM, Jiang LX, Chen YP , et al; COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366 (9497) 1607-1621
    CrossrefPubMedGoogle Scholar
  • 29 Sabatine MS, Cannon CP, Gibson CM , et al; CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352 (12) 1179-1189
    CrossrefPubMedGoogle Scholar
  • 30 Matetzky S, Shenkman B, Guetta V , et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109 (25) 3171-3175
    CrossrefPubMedGoogle Scholar
  • 31 Cuisset T, Frere C, Quilici J , et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006; 4 (3) 542-549
    CrossrefPubMedGoogle Scholar
  • 32 Gurbel PA, Lau WC, Bliden KP, Tantry US. Clopidogrel resistance: implications for coronary stenting. Curr Pharm Des 2006; 12 (10) 1261-1269
    CrossrefPubMedGoogle Scholar
  • 33 Wiviott SD, Trenk D, Frelinger AL , et al; PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007; 116 (25) 2923-2932
    CrossrefPubMedGoogle Scholar
  • 34 Antman EM, Wiviott SD, Murphy SA , et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol 2008; 51 (21) 2028-2033
    CrossrefPubMedGoogle Scholar
  • 35 Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41 (6) 961-965
    CrossrefPubMedGoogle Scholar
  • 36 Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105 (14) 1650-1655
    CrossrefPubMedGoogle Scholar
  • 37 Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008; 336 (7637) 195-198
    CrossrefPubMedGoogle Scholar
  • 38 Lippi G, Favaloro EJ, Salvagno GL, Franchini M. Laboratory assessment and perioperative management of patients on antiplatelet therapy: from the bench to the bedside. Clin Chim Acta 2009; 405 (1-2) 8-16
    CrossrefPubMedGoogle Scholar
  • 39 Favaloro EJ, Lippi G, Franchini M. Contemporary platelet function testing. Clin Chem Lab Med 2010; 48 (5) 579-598
    CrossrefPubMedGoogle Scholar
  • 40 Michelson AD, Cattaneo M, Eikelboom JW , et al; Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis; Working Group on Aspirin Resistance. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005; 3 (6) 1309-1311
    CrossrefPubMedGoogle Scholar
  • 41 Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 2003; 1 (8) 1710-1713
    CrossrefPubMedGoogle Scholar
  • 42 Bonello L, Tantry US, Marcucci R , et al; Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56 (12) 919-933
    CrossrefPubMedGoogle Scholar
  • 43 Cattaneo M. Laboratory detection of ‘aspirin resistance’: what test should we use (if any)?. Eur Heart J 2007; 28 (14) 1673-1675
    CrossrefPubMedGoogle Scholar
  • 44 Sweeny JM, Gorog DA, Fuster V. Antiplatelet drug ‘resistance’. Part 1: mechanisms and clinical measurements. Nat Rev Cardiol 2009; 6 (4) 273-282
    CrossrefPubMedGoogle Scholar
  • 45 Mattiello T, Guerriero R, Lotti LV , et al. Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: evidence of a reduced drug action in patients after coronary artery bypass grafting. J Am Coll Cardiol 2011; 58 (7) 752-761
    CrossrefPubMedGoogle Scholar
  • 46 Frelinger AL, Li Y, Linden MD , et al. Aspirin ‘resistance’: role of pre-existent platelet reactivity and correlation between tests. J Thromb Haemost 2008; 6 (12) 2035-2044
    CrossrefPubMedGoogle Scholar
  • 47 Hughes CM. Medication non-adherence in the elderly: how big is the problem?. Drugs Aging 2004; 21 (12) 793-811
    CrossrefPubMedGoogle Scholar
  • 48 Waeber B, Leonetti G, Kolloch R, McInnes GT. Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study. J Hypertens 1999; 17 (7) 1041-1045
    CrossrefPubMedGoogle Scholar
  • 49 Glynn RJ, Buring JE, Manson JE, LaMotte F, Hennekens CH. Adherence to aspirin in the prevention of myocardial infarction. The Physicians’ Health Study. Arch Intern Med 1994; 154 (23) 2649-2657
    CrossrefPubMedGoogle Scholar
  • 50 Dyken ML, Barnett HJ, Easton JD , et al. Low-dose aspirin and stroke. “It ain’t necessarily so”. Stroke 1992; 23 (10) 1395-1399
    CrossrefPubMedGoogle Scholar
  • 51 Kong DF. Aspirin in cardiovascular disorders. What is the optimum dose?. Am J Cardiovasc Drugs 2004; 4 (3) 151-158
    CrossrefPubMedGoogle Scholar
  • 52 Patrono C. Prevention of myocardial infarction and stroke by aspirin: different mechanisms? Different dosage?. Thromb Res 1998; 92 (1, Suppl 1) S7-S12
    CrossrefPubMedGoogle Scholar
  • 53 Frelinger III AL, Li Y, Linden MD , et al. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation 2009; 120 (25) 2586-2596
    CrossrefPubMedGoogle Scholar
  • 54 Patrono C, Coller B, Dalen JE , et al. Platelet-active drugs : the relationships among dose, effectiveness, and side effects. Chest 2001; 119 (1, Suppl) 39S-63S
    CrossrefPubMedGoogle Scholar
  • 55 Taylor DW, Barnett HJ, Haynes RB , et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet 1999; 353 (9171) 2179-2184
    Google Scholar
  • 56 The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325 (18) 1261-1266
    CrossrefPubMedGoogle Scholar
  • 57 Harris WH, Athanasoulis CA, Waltman AC, Salzman EW. Prophylaxis of deep-vein thrombosis after total hip replacement. Dextran and external pneumatic compression compared with 1.2 or 0.3 gram of aspirin daily. J Bone Joint Surg Am 1985; 67 (1) 57-62
    PubMedGoogle Scholar
  • 58 Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69 (6) 1366-1372
    CrossrefPubMedGoogle Scholar
  • 59 Weksler BB, Pett SB, Alonso D , et al. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med 1983; 308 (14) 800-805
    CrossrefPubMedGoogle Scholar
  • 60 Kurth T, Glynn RJ, Walker AM , et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 2003; 108 (10) 1191-1195
    CrossrefPubMedGoogle Scholar
  • 61 MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361 (9357) 573-574
    CrossrefPubMedGoogle Scholar
  • 62 Linden MD, Frelinger III AL, Przyklenk K, Furman MI, Michelson AD. Aspirin resistance: detection, mechanisms, and clinical implications. Curr Cardiol Rev 2005; 1 (3) 203-211
    CrossrefPubMedGoogle Scholar
  • 63 Umar A, Boisseau M, Yusup A, Upur H, Bégaud B, Moore N. Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model. Fundam Clin Pharmacol 2004; 18 (5) 559-563
    CrossrefPubMedGoogle Scholar
  • 64 Lévesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 2005; 142 (7) 481-489
    PubMedGoogle Scholar
  • 65 Solomon DH, Schneeweiss S, Levin R, Avorn J. Relationship between COX-2 specific inhibitors and hypertension. Hypertension 2004; 44 (2) 140-145
    CrossrefPubMedGoogle Scholar
  • 66 Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286 (8) 954-959
    CrossrefPubMedGoogle Scholar
  • 67 Di Minno G. Aspirin resistance and platelet turnover: a 25-year old issue. Nutr Metab Cardiovasc Dis 2011; 21 (8) 542-545
    CrossrefPubMedGoogle Scholar
  • 68 Cambria-Kiely JA, Gandhi PJ. Aspirin resistance and genetic polymorphisms. J Thromb Thrombolysis 2002; 14 (1) 51-58
    CrossrefPubMedGoogle Scholar
  • 69 Censarek P, Freidel K, Udelhoven M , et al. Cyclooxygenase COX-2a, a novel COX-2 mRNA variant, in platelets from patients after coronary artery bypass grafting. Thromb Haemost 2004; 92 (5) 925-928
    PubMedGoogle Scholar
  • 70 Weber AA, Zimmermann KC, Meyer-Kirchrath J, Schrör K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 1999; 353 (9156) 900
    PubMedGoogle Scholar
  • 71 Schuster VL. Molecular mechanisms of prostaglandin transport. Annu Rev Physiol 1998; 60: 221-242
    CrossrefPubMedGoogle Scholar
  • 72 Maclouf J, Folco G, Patrono C. Eicosanoids and iso-eicosanoids: constitutive, inducible and transcellular biosynthesis in vascular disease. Thromb Haemost 1998; 79 (4) 691-705
    PubMedGoogle Scholar
  • 73 Frelinger III AL, Furman MI, Linden MD , et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 2006; 113 (25) 2888-2896
    CrossrefPubMedGoogle Scholar
  • 74 Freedman JE. The aspirin resistance controversy: clinical entity or platelet heterogeneity?. Circulation 2006; 113 (25) 2865-2867
    CrossrefPubMedGoogle Scholar
  • 75 Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357 (24) 2482-2494
    CrossrefPubMedGoogle Scholar
  • 76 Furman MI, Benoit SE, Barnard MR , et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 1998; 31 (2) 352-358
    CrossrefPubMedGoogle Scholar
  • 77 Linden MD, Furman MI, Frelinger III AL , et al. Indices of platelet activation and the stability of coronary artery disease. J Thromb Haemost 2007; 5 (4) 761-765
    CrossrefPubMedGoogle Scholar
  • 78 Ajjan R, Storey RF, Grant PJ. Aspirin resistance and diabetes mellitus. Diabetologia 2008; 51 (3) 385-390
    CrossrefPubMedGoogle Scholar
  • 79 Ferreira IA, Mocking AI, Feijge MA , et al. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2006; 26 (2) 417-422
    PubMedGoogle Scholar
  • 80 Angiolillo DJ. Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care 2009; 32 (4) 531-540
    CrossrefPubMedGoogle Scholar
  • 81 Akoglu H, Agbaht K, Piskinpasa S , et al. High frequency of aspirin resistance in patients with nephrotic syndrome. Nephrol Dial Transplant 2011; ; August 23 DOI: 10.1093/ndt/gfr476 [Epub ahead of print]
    PubMedGoogle Scholar
  • 82 Tanrikulu AM, Ozben B, Koc M, Papila-Topal N, Ozben T, Caymaz O. Aspirin resistance in patients with chronic renal failure. J Nephrol 2011; 24 (5) 636-646
    CrossrefPubMedGoogle Scholar
  • 83 Harrison P, Frelinger III AL, Furman MI, Michelson AD. Measuring antiplatelet drug effects in the laboratory. Thromb Res 2007; 120 (3) 323-336
    CrossrefPubMedGoogle Scholar
  • 84 Michelson AD, Frelinger III AL, Furman MI. Resistance to antiplatelet drugs. Eur Heart J 2006; 8: G53-G58
    CrossrefPubMedGoogle Scholar
  • 85 Catella F, FitzGerald GA. Paired analysis of urinary thromboxane B2 metabolites in humans. Thromb Res 1987; 47 (6) 647-656
    CrossrefPubMedGoogle Scholar
  • 86 Kazui M, Nishiya Y, Ishizuka T , et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010; 38 (1) 92-99
    CrossrefPubMedGoogle Scholar
  • 87 Lau WC, Gurbel PA, Watkins PB , et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004; 109 (2) 166-171
    CrossrefPubMedGoogle Scholar
  • 88 Mega JL, Close SL, Wiviott SD , et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360 (4) 354-362
    CrossrefPubMedGoogle Scholar
  • 89 Shuldiner AR, O’Connell JR, Bliden KP , et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302 (8) 849-857
    CrossrefPubMedGoogle Scholar
  • 90 Sibbing D, Gebhard D, Koch W , et al. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J Thromb Haemost 2010; 8 (8) 1685-1693
    CrossrefPubMedGoogle Scholar
  • 91 Simon T, Verstuyft C, Mary-Krause M , et al; French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360 (4) 363-375
    CrossrefPubMedGoogle Scholar
  • 92 Trenk D, Hochholzer W, Fromm MF , et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008; 51 (20) 1925-1934
    CrossrefPubMedGoogle Scholar
  • 93 Holmes Jr DR, Dehmer GJ, Kaul S, Leifer D, O’Gara PT, Stein CM ; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; Writing Committee Members. ACCF/AHA Clopidogrel clinical alert: approaches to the FDA “boxed warning”: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation 2010; 122 (5) 537-557
    CrossrefPubMedGoogle Scholar
  • 94 Mega JL, Simon T, Collet JP , et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010; 304 (16) 1821-1830
    CrossrefPubMedGoogle Scholar
  • 95 Kassimis G, Davlouros P, Xanthopoulou I, Stavrou EF, Athanassiadou A, Alexopoulos D. CYP2C19*2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention. Thromb Res 2011; ; DOI: 10.1016/j.thromb.2011.07.022 August 8 [Epub ahead of print]
    PubMedGoogle Scholar
  • 96 Wallentin L, James S, Storey RF , et al; PLATO investigators. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010; 376 (9749) 1320-1328
    CrossrefPubMedGoogle Scholar
  • 97 Sibbing D, Byrne RA, Bernlochner I, Kastrati A. High platelet reactivity and clinical outcome - fact and fiction. Thromb Haemost 2011; 106 (2) 191-202
    Article in Thieme ConnectPubMedGoogle Scholar
  • 98 Serebruany V, Cherala G, Williams C , et al. Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of “resistance”. Am Heart J 2009; 158 (6) 925-932
    CrossrefPubMedGoogle Scholar
  • 99 Osmancik P, Jirmar R, Hulikova K , et al. A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction. Catheter Cardiovasc Interv 2010; 75 (2) 158-166
    CrossrefPubMedGoogle Scholar
  • 100 Gurbel PA, Antonino MJ, Tantry US. Recent developments in clopidogrel pharmacology and their relation to clinical outcomes. Expert Opin Drug Metab Toxicol 2009; 5 (8) 989-1004
    CrossrefPubMedGoogle Scholar
  • 101 Sibbing D, von Beckerath O, Schömig A, Kastrati A, von Beckerath N. Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. Am J Cardiol 2007; 100 (2) 203-205
    CrossrefPubMedGoogle Scholar
  • 102 Angiolillo DJ, Fernández-Ortiz A, Bernardo E , et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?. J Invasive Cardiol 2004; 16 (4) 169-174
    PubMedGoogle Scholar
  • 103 Gladding P, Webster M, Zeng I , et al. The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc Interv 2008; 1 (6) 612-619
    CrossrefPubMedGoogle Scholar
  • 104 Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005; 111 (16) 2099-2106
    CrossrefPubMedGoogle Scholar
  • 105 Collet JP, Hulot JS, Anzaha G , et al; CLOVIS-2 Investigators. High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2). JACC Cardiovasc Interv 2011; 4 (4) 392-402
    PubMedGoogle Scholar
  • 106 Sibbing D, Morath T, Stegherr J , et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009; 101 (4) 714-719
    PubMedGoogle Scholar
  • 107 Sibbing D, Kastrati A. Risk of combining PPIs with thienopyridines: fact or fiction?. Lancet 2009; 374 (9694) 952-954
    CrossrefPubMedGoogle Scholar
  • 108 Trenk D, Hochholzer W, Frundi D , et al. Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement. Thromb Haemost 2008; 99 (1) 174-181
    PubMedGoogle Scholar
  • 109 Moceri P, Doyen D, Cerboni P, Ferrari E. Doubling the dose of clopidogrel restores the loss of antiplatelet effect induced by esomeprazole. Thromb Res 2011; 128 (5) 458-462
    CrossrefPubMedGoogle Scholar
  • 110 Michelson AD, Linden MD, Furman MI , et al. Evidence that pre-existent variability in platelet response to ADP accounts for ‘clopidogrel resistance’. J Thromb Haemost 2007; 5 (1) 75-81
    CrossrefPubMedGoogle Scholar
  • 111 Grdinic A, Vojvodic D, Djukanovic N , et al. PCI and clopidogrel: antiplatelet responsiveness and patient characteristics. Acta Cardiol 2011; 66 (3) 333-340
    PubMedGoogle Scholar
  • 112 Angiolillo DJ, Fernandez-Ortiz A, Bernardo E , et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005; 54 (8) 2430-2435
    CrossrefPubMedGoogle Scholar
  • 113 Angiolillo DJ, Badimon JJ, Saucedo JF , et al. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. Eur Heart J 2011; 32 (7) 838-846
    CrossrefPubMedGoogle Scholar
  • 114 Park SH, Kim W, Park CS, Kang WY, Hwang SH, Kim W. A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. Am J Cardiol 2009; 104 (9) 1292-1295
    CrossrefPubMedGoogle Scholar
  • 115 Camilleri E, Jacquin L, Paganelli F, Bonello L. Personalized antiplatelet therapy: review of the latest clinical evidence. Curr Cardiol Rep 2011; 13 (4) 296-302
    CrossrefPubMedGoogle Scholar
  • 116 Breet NJ, van Werkum JW, Bouman HJ , et al. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention. Heart 2011; 97 (12) 983-990
    CrossrefPubMedGoogle Scholar
  • 117 Cotter G, Shemesh E, Zehavi M , et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin?. Am Heart J 2004; 147 (2) 293-300
    CrossrefPubMedGoogle Scholar
  • 118 Stejskal D, Václavík J, Lacnák B, Prosková J. Aspirin resistance measured by cationic propyl gallate platelet aggregometry and recurrent cardiovascular events during 4 years of follow-up. Eur J Intern Med 2006; 17 (5) 349-354
    CrossrefPubMedGoogle Scholar
  • 119 Helgason CM, Bolin KM, Hoff JA , et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994; 25 (12) 2331-2336
    CrossrefPubMedGoogle Scholar
  • 120 Mueller MR, Salat A, Stangl P , et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997; 78 (3) 1003-1007
    PubMedGoogle Scholar
  • 121 Poston RS, Gu J, Brown JM , et al. Endothelial injury and acquired aspirin resistance as promoters of regional thrombin formation and early vein graft failure after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2006; 131 (1) 122-130
    CrossrefPubMedGoogle Scholar
  • 122 Berrouschot J, Schwetlick B, von Twickel G , et al. Aspirin resistance in secondary stroke prevention. Acta Neurol Scand 2006; 113 (1) 31-35
    CrossrefPubMedGoogle Scholar
  • 123 Zhang Y, Liang J, Zhou YJ, Yuan H, Zhang YZ, Dong L. [Study on the relationship between aspirin resistance and incidence of myonecrosis after non-emergent percutaneous coronary intervention]. Zhonghua Xin Xue Guan Bing Za Zhi 2005; 33 (8) 695-699
    PubMedGoogle Scholar
  • 124 Borna C, Lazarowski E, van Heusden C, Ohlin H, Erlinge D. Resistance to aspirin is increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels. Thromb J 2005; 3: 10
    CrossrefPubMedGoogle Scholar
  • 125 Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003; 250 (1) 63-66
    CrossrefPubMedGoogle Scholar
  • 126 Hobikoglu GF, Norgaz T, Aksu H , et al. High frequency of aspirin resistance in patients with acute coronary syndrome. Tohoku J Exp Med 2005; 207 (1) 59-64
    CrossrefPubMedGoogle Scholar
  • 127 McCabe DJ, Harrison P, Mackie IJ , et al. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. Platelets 2005; 16 (5) 269-280
    CrossrefPubMedGoogle Scholar
  • 128 Yilmaz MB, Balbay Y, Caldir V , et al. Late saphenous vein graft occlusion in patients with coronary bypass: possible role of aspirin resistance. Thromb Res 2005; 115 (1-2) 25-29
    CrossrefPubMedGoogle Scholar
  • 129 Pamukcu B, Oflaz H, Onur I , et al. Aspirin-resistant platelet aggregation in a cohort of patients with coronary heart disease. Blood Coagul Fibrinolysis 2007; 18 (5) 461-465
    CrossrefPubMedGoogle Scholar
  • 130 Macchi L, Christiaens L, Brabant S , et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 2002; 107 (1-2) 45-49
    CrossrefPubMedGoogle Scholar
  • 131 Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2002; 108 (1) 37-42
    CrossrefPubMedGoogle Scholar
  • 132 Golański J, Nocuń M, Rózalski M, Drygas W, Watała C. An in vitro model for the detection of reduced platelet sensitivity to acetylsalicylic acid. Blood Coagul Fibrinolysis 2004; 15 (2) 187-195
    CrossrefPubMedGoogle Scholar
  • 133 Buchanan MR, Schwartz L, Bourassa M, Brister SJ, Peniston CM ; BRAT Investigators. Results of the BRAT study—a pilot study investigating the possible significance of ASA nonresponsiveness on the benefits and risks of ASA on thrombosis in patients undergoing coronary artery bypass surgery. Can J Cardiol 2000; 16 (11) 1385-1390
    PubMedGoogle Scholar
  • 134 Gurbel PA, Bliden KP. A new method of representing drug-induced platelet inhibition: better description of time course, response variability, non-response, and heightened activity. Platelets 2003; 14 (7-8) 481-483
    CrossrefPubMedGoogle Scholar
  • 135 Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005; 46 (9) 1705-1709
    CrossrefPubMedGoogle Scholar
  • 136 Chen WH, Lee PY, Ng W , et al. Relation of aspirin resistance to coronary flow reserve in patients undergoing elective percutaneous coronary intervention. Am J Cardiol 2005; 96 (6) 760-763
    CrossrefPubMedGoogle Scholar
  • 137 Chen WH, Lee PY, Ng W, Tse HF, Lau CP. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004; 43 (6) 1122-1126
    CrossrefPubMedGoogle Scholar
  • 138 Wang JC, Aucoin-Barry D, Manuelian D , et al. Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Am J Cardiol 2003; 92 (12) 1492-1494
    CrossrefPubMedGoogle Scholar
  • 139 Breet NJ, van Werkum JW, Bouman HJ , et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010; 303 (8) 754-762
    CrossrefPubMedGoogle Scholar
  • 140 Buonamici P, Marcucci R, Migliorini A , et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007; 49 (24) 2312-2317
    CrossrefPubMedGoogle Scholar
  • 141 Cuisset T, Cayla G, Frere C , et al. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment?. EuroIntervention 2009; 5 (3) 325-329
    CrossrefPubMedGoogle Scholar
  • 142 Frere C, Cuisset T, Quilici J , et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost 2007; 98 (4) 838-843
    PubMedGoogle Scholar
  • 143 Geisler T, Zürn C, Simonenko R , et al. Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J 2010; 31 (1) 59-66
    CrossrefPubMedGoogle Scholar
  • 144 Geisler T, Langer H, Wydymus M , et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006; 27 (20) 2420-2425
    CrossrefPubMedGoogle Scholar
  • 145 Gori AM, Marcucci R, Migliorini A , et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol 2008; 52 (9) 734-739
    CrossrefPubMedGoogle Scholar
  • 146 Gurbel PA, Antonino MJ, Bliden KP , et al. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target. Platelets 2008; 19 (8) 595-604
    CrossrefPubMedGoogle Scholar
  • 147 Gurbel PA, Bliden KP, Guyer K , et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005; 46 (10) 1820-1826
    CrossrefPubMedGoogle Scholar
  • 148 Gurbel PA, Bliden KP, Samara W , et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005; 46 (10) 1827-1832
    CrossrefPubMedGoogle Scholar
  • 149 Hochholzer W, Trenk D, Bestehorn HP , et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48 (9) 1742-1750
    CrossrefPubMedGoogle Scholar
  • 150 Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?. J Am Coll Cardiol 2007; 49 (6) 657-666
    CrossrefPubMedGoogle Scholar
  • 151 Lev EI, Patel RT, Maresh KJ , et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006; 47 (1) 27-33
    CrossrefPubMedGoogle Scholar
  • 152 Cuisset T, Frere C, Quilici J , et al. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. Thromb Haemost 2007; 97 (2) 282-287
    PubMedGoogle Scholar
  • 153 Barragan P, Bouvier JL, Roquebert PO , et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003; 59 (3) 295-302
    CrossrefPubMedGoogle Scholar
  • 154 Blindt R, Stellbrink K, de Taeye A , et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 2007; 98 (6) 1329-1334
    PubMedGoogle Scholar
  • 155 Bonello L, Paganelli F, Arpin-Bornet M , et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007; 5 (8) 1630-1636
    CrossrefPubMedGoogle Scholar
  • 156 Linnemann B, Schwonberg J, Rechner AR, Mani H, Lindhoff-Last E. Assessment of clopidogrel non-response by the PFA-100 system using the new test cartridge INNOVANCE PFA P2Y. Ann Hematol 2010; 89 (6) 597-605
    CrossrefPubMedGoogle Scholar
  • 157 McGlasson DL, Shah AD, Fritsma GA. Ability of the INNOVANCE PFA P2Y system to detect clopidogrel-induced ADP receptor blockade in preangiocath individuals. Blood Coagul Fibrinolysis 2011; 22 (7) 583-587
    CrossrefPubMedGoogle Scholar
  • 158 Marcucci R, Gori AM, Paniccia R , et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009; 119 (2) 237-242
    CrossrefPubMedGoogle Scholar
  • 159 Migliorini A, Valenti R, Marcucci R , et al. High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease. Circulation 2009; 120 (22) 2214-2221
    CrossrefPubMedGoogle Scholar
  • 160 Patti G, Nusca A, Mangiacapra F, Gatto L, D’Ambrosio A, Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 2008; 52 (14) 1128-1133
    CrossrefPubMedGoogle Scholar
  • 161 Price MJ, Endemann S, Gollapudi RR , et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008; 29 (8) 992-1000
    CrossrefPubMedGoogle Scholar
  • 162 Valgimigli M, Campo G, de Cesare N , et al; Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. Circulation 2009; 119 (25) 3215-3222
    CrossrefPubMedGoogle Scholar